Texas Capital Bancshares Inc
Change company Symbol lookup
Select an option...
TCBI Texas Capital Bancshares Inc
IBB iShares Nasdaq Biotechnology ETF
NEP Nextera Energy Partners LP
FRAN Francesca's Holdings Corp
CDTI CDTi Advanced Materials Inc
UBER Uber Technologies Inc
MTX Minerals Technologies Inc
PRGS Progress Software Corp
CODA Coda Octopus Group Inc
WAB Westinghouse Air Brake Technologies Corp
Go

Financials : Banks | Small Cap Growth
Company profile

Texas Capital Bancshares, Inc. is a bank holding and a financial holding company. The Company is the parent of Texas Capital Bank, National Association (the Bank). It offers a range of loan, deposit account and other financial products and services to its customers. It offers a range of products and services for its business customers, including commercial loans for general corporate purposes, including financing for working capital, internal growth, acquisitions and financing for business insurance premiums; medium- and long-term tax-exempt loans for municipalities and other governmental and tax-exempt entities; wealth management and trust services, and letters of credit. It also provides banking services for its individual customers, including personal wealth management and trust services; certificates of deposit; interest-bearing and non-interest-bearing checking accounts; traditional money market and savings accounts; loans, both secured and unsecured, and Internet banking.

Postmarket

Last Trade
Delayed
$38.75
0.23 (0.60%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$38.52
Day's Change
1.21 (3.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
38.84
Day's Low
37.15
Volume
(Heavy Day)
Volume:
464,851

10-day average volume:
341,646
464,851

Beyond Celiac Encouraged By Increasing Awareness of Economic Burden of Celiac Disease

1:57 pm ET September 15, 2020 (Globe Newswire) Print

Beyond Celiac, the leading accelerator for a celiac disease cure in the United States, sees a new study showing celiac disease patients face a significant economic burden from higher healthcare costs as an important step in the ongoing work to advance research and accelerate the discovery of new treatments.

In a study published in the American Journal of Gastroenterology, researchers from IBM Watson Health, Takeda Pharmaceuticals and Beth Israel Deaconess Medical Center found that in the year prior to diagnosis, those with celiac disease paid an average of about $4,000 more in all healthcare costs than controls. In the first year of follow-up, celiac disease patients paid an average of about $8,000 more than controls and in the second year, about $4,000 more. The study authors suggest that therapies that could improve disease control could result in lower overall cost to the healthcare system.

"This study illustrates the importance of building more awareness of the burden of celiac disease," said Salvo Alesci, MD, Beyond Celiac chief scientist and strategy officer. "There is a burden born by patients and a burden on the healthcare system. Both can be reduced by accelerating the development of treatments for celiac disease and then making sure they become widely accessible to patients who need them."

Beyond Celiac has been bringing together patients, researchers and pharmaceutical company, health insurance and Food and Drug Administration representatives to discuss the true economic impact of celiac disease, including missed work and school, as well as use of the healthcare system to deal with both the symptoms and complications of celiac disease. At the 2019 Beyond Celiac Research Summit, recognition and understanding of these burdens by scientists, federal regulators and health insurance companies was identified as key to getting past some of the barriers that have prevented celiac disease research from resulting in new treatment for patients.

"Beyond Celiac will continue to voice these concerns, and we applaud diligent research like this study that propels progress towards a cure," added Alice Bast, CEO of Beyond Celiac.

Celiac disease is a serious genetic autoimmune disorder that affects an estimated 1 in 133 Americans, more than half of whom are still undiagnosed. The disease causes damage to the small intestine, resulting in debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

About Beyond Celiac

Founded in 2003, Beyond Celiac is the leading catalyst for a celiac disease cure in the United States, serving as a patient advocacy and research-driven organization working to drive diagnosis, advance research and accelerate the discovery of new treatments. By engaging with the top scientists in the field, making the right investments in research and supporting the broad community of those with celiac disease and gluten sensitivity, Beyond Celiac envisions a world in which people can live healthy lives and eat without fear - a world Beyond Celiac. www.BeyondCeliac.org.

Attachment

-- Salvo Alesci, MD

Claire Baker
Beyond Celiac
267-419-2111
cbaker@beyondceliac.org
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.